Targeting Refractory Triple-Negative Breast Cancer with Sacituzumab Govitecan: A New Era in Precision Medicine

Advanced triple-negative breast cancer (TNBC) has poorer outcomes due to its aggressive behavior and restricted therapeutic options. While therapies like checkpoint inhibitors and PARP inhibitors offer some benefits, chemotherapy remains ineffective beyond the first line of treatment. Antibody–drug...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Saif Khan, Suresh Babu Jandrajupalli, Nashwa Zaki Ali Bushara, Rama Devi Patel Raja, Shadab Mirza, Kuldeep Sharma, Rajan Verma, Ashish Kumar, Mohtashim Lohani
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	MDPI AG 2024-12-01
Edice:	Cells
Témata:	triple-negative breast cancer (TNBC) antibody–drug conjugates sacituzumab govitecan neutropenia ADC sequencing resistance
On-line přístup:	https://www.mdpi.com/2073-4409/13/24/2126
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!